Transcept Pharmaceuticals to Report Third Quarter 2013 Financial Results and Host Conference Call on November 7, 2013

 Transcept Pharmaceuticals to Report Third Quarter 2013 Financial Results and
                   Host Conference Call on November 7, 2013

PR Newswire

POINT RICHMOND, Calif., Nov. 4, 2013

POINT RICHMOND, Calif., Nov. 4, 2013 /PRNewswire/ -- Transcept
Pharmaceuticals, Inc. (Nasdaq: TSPT), a specialty pharmaceutical company
focused on the development and commercialization of proprietary products that
address important therapeutic needs in the field of neuroscience, today
announced that the company will host a conference call on Thursday, November
7, 2013, at 4:30 p.m. Eastern Time to discuss its third quarter 2013 financial
results. The conference call will follow the release of the Transcept third
quarter 2013 financial results after the close of market that day.

Conference Call Information

Date: Thursday, November 7, 2013
Time: 4:30 p.m. ET
Dial-in (U.S.): (877) 638-4558
Dial-in (International): (914) 495-8537

A simultaneous webcast of the conference call will be available on the
Investors section of the Transcept website at www.transcept.com. A replay of
this webcast will be available on the website shortly after the conclusion of
the call and will be available through December 31, 2013.

About Transcept

Transcept Pharmaceuticals, Inc.is a specialty pharmaceutical company focused
on the development and commercialization of proprietary products to address
important therapeutic needs in the field of neuroscience. The company's lead
development candidate is TO-2070, a novel, rapidly absorbed treatment for
acute migraine incorporating dihydroergotamine (DHE) as the active drug.
Preclinical data suggest that TO-2070 may offer significant migraine treatment
benefits beyond those provided by less convenient and more invasive DHE drug
delivery methods, such as injection, liquid nasal sprays or pulmonary
inhalation.

In addition to advancing TO-2070, Transcept is continuing to evaluate
opportunities to supplement its development pipeline with new programs
appropriate to its area of expertise. The company's management team developed
Intermezzo®from concept to its approval by theFDAin 2011.Purdueholds
commercialization and development rights for Intermezzo in the United
States.For further information about Transcept, please visit
www.transcept.com. For information about Intermezzo, please
visitwww.MyIntermezzo.com.

Contact:

Transcept Pharmaceuticals, Inc.
Leone Patterson
Vice President and Chief Financial Officer
(510) 215-3512
lpatterson@transcept.com

SOURCE Transcept Pharmaceuticals, Inc.

Website: http://www.transcept.com
 
Press spacebar to pause and continue. Press esc to stop.